ArticleJournal of hepatocellular carcinoma2026
From Tumor to Tumor-Spleen: MRI Habitat Heterogeneity for Predicting Immunotherapy Outcome in Advanced Hepatocellular Carcinoma.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop and validate a pretreatment MRI-based radiomics model that integrates tumor and spleen habitat heterogeneity features for predicting objective response to immunotherapy and stratifying progression-free survival (PFS) in patients with advanced hepatocellular carcinoma (HCC). Methods: In this retrospective study, 107 patients with advanced HCC receiving first-line immunotherapy were included. Tumor and spleen habitats were independently identified on portal venous phase MRI using K-means clustering. High-throughput radiomic features were extracted from each habitat, and their spatial heterogeneity was quantified to generate predictive signatures. These features were integrated into a weighted fusion model (RadCVTS) to predict objective response. Model performance was evaluated in a temporal validation cohort, with comparison against a tumor-only heterogeneity model (RadCVT) and a conventional tumor radiomics model (RadT). Association with PFS was assessed using Kaplan-Meier analysis and Cox regression. Results: The RadCVTS demonstrated superior predictive performance compared to both the RadCVT and the conventional RadT,with AUCs of 0.958 vs 0.828 vs 0.789, respectively, in the temporal validation cohort. Patients stratified as high-risk by the model had significantly shorter PFS than the low-risk group (hazard ratio: 11.44, p < 0.05). Exploratory analysis of the top two features from the tumor and spleen, respectively, revealed that patients exhibiting a "Double-High" imaging phenotype had a 22.5 times greater odds of response than the "Double-Low" group. A simplified model using only these two features also provided significant incremental value for PFS prediction (AUC = 0.802). Conclusion: The tumor-spleen combined habitat heterogeneity model demonstrated superior predictive performance over both the tumor-only heterogeneity model and the conventional tumor radiomics model, and can noninvasively predict response to immunotherapy and stratify PFS in advanced HCC, highlighting the value of the liver-spleen axis and providing a promising indicator to support personalized treatment decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.